Most-Cited Alzheimer's Disease Papers This Year (2026)
As of November 2, 2026, “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials” leads Most-Cited Alzheimer's Disease Papers This Year with 92 citations. “The TREM2 agonistic antibody AL002 in early Alzheimer’s disease: a phase 2 randomized trial” is second and “TREM2 expression level is critical for microglial state, metabolic capacity and efficacy of TREM2 agonism” third. Biggest climber: “Engineering chimeric antigen receptor CD4 T cells for Alzheimer’s disease” (▲1).
Full ranking
How this ranking works
Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.
Frequently asked questions
What is #1 in Most-Cited Alzheimer's Disease Papers This Year?
As of November 2, 2026, #1 is “Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials”.
How is this ranking measured?
Ranked by citation count (OpenAlex) among research papers published this year whose title or abstract matches this topic. Citations build up over time, so the newest papers rank lower. For information only, not medical advice.
How often is this chart updated?
Data is re-collected automatically and every page shows its last update date.
Can a brand pay to appear in this ranking?
No. There are no paid placements and no commercial influence on rank.
More rankings for you
🌍 Worldwide
Most Played PC Games Right Now
Dota 2•
PUBG: BATTLEGROUNDS•
Wallpaper Engine•Top Tech Stories Today
🌍 Worldwide
Trending Open-Source Projects This Week
heydamir/unslop▲1
anhao/ai-pose-gallery-zh▼1
wangzan101/Mika•